30 results
8-K
EX-99.5
KANT
Kineta, Inc.
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
the benefit of those transactions if Kineta is unable to successfully integrate them with Kineta’s existing operations and company culture, which could
424B3
KANT
Kineta, Inc.
10 Nov 22
Prospectus supplement
4:21pm
operations and company culture. In addition, if Yumanity’s agreement with any of its collaborators terminates, Yumanity’s access to technology … to successfully integrate them with its existing operations and company culture. Yumanity may encounter numerous difficulties in developing, manufacturing
8-K
EX-10.1
qmcq kthf5uuqgqn
4 Mar 22
Entry into a Material Definitive Agreement
4:15pm
8-K
EX-99.1
3rad6gifng
17 May 21
Regulation FD Disclosure
5:03pm
8-K/A
EX-99.3
ozp2 9wtuitabuf
3 Feb 21
Other Events
4:59pm
8-K/A
EX-99.1
uv4 2qefxga5hg
3 Feb 21
Other Events
4:59pm